2017 Q2 Form 10-K Financial Statement

#000114420417052475 Filed on October 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 2016 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $410.0K $3.990M $290.0K
YoY Change 41.38% 147.83% 141.67%
% of Gross Profit
Research & Development $2.595M $16.40M $410.0K
YoY Change 532.93% 82.48% -51.19%
% of Gross Profit
Depreciation & Amortization $7.000K $39.00K $10.00K
YoY Change -30.0% 387.5% -75.0%
% of Gross Profit
Operating Expenses $3.179M $20.39M $1.400M
YoY Change 127.07% 107.22% 45.83%
Operating Profit -$3.179M -$20.39M
YoY Change 107.22%
Interest Expense -$1.470M -$74.00 $30.00K
YoY Change -5000.0% -86.12%
% of Operating Profit
Other Income/Expense, Net -$699.0K -$824.0K -$60.00K
YoY Change 1065.0% 11671.43% -700.0%
Pretax Income -$2.010M -$21.21M -$1.430M
YoY Change 40.56% 115.44% 57.14%
Income Tax $0.00 -$640.0K -$280.0K
% Of Pretax Income
Net Earnings -$3.878M -$21.21M -$1.150M
YoY Change 237.22% 115.44% 26.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.436M -$4.259M -$1.127M
COMMON SHARES
Basic Shares Outstanding 26.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.00K $24.05M $810.0K
YoY Change -96.3% 2869.14% -75.68%
Cash & Equivalents $13.36M $24.05M $810.8K
Short-Term Investments
Other Short-Term Assets $250.0K $460.0K $170.0K
YoY Change 47.06% 170.59% -57.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $280.0K $24.51M $982.6K
YoY Change -71.5% 2401.02% -73.65%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K $280.0K $92.55K
YoY Change -45.98% 211.11% -50.23%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $50.00K
YoY Change -80.0% 0.0%
Total Long-Term Assets $5.565M $270.0K $8.243M
YoY Change -32.49% -96.73% -47.89%
TOTAL ASSETS
Total Short-Term Assets $280.0K $24.51M $982.6K
Total Long-Term Assets $5.565M $270.0K $8.243M
Total Assets $5.845M $24.78M $9.226M
YoY Change -36.64% 168.47% -52.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $191.6K $1.530M $90.31K
YoY Change 112.17% 1600.0% -61.08%
Accrued Expenses $330.3K $1.890M $256.4K
YoY Change 28.83% 626.92% -37.27%
Deferred Revenue
YoY Change
Short-Term Debt $410.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.770M $3.420M $369.0K
YoY Change 650.7% 824.32% -52.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $99.73K
YoY Change -100.0% -18.28%
Total Long-Term Liabilities $0.00 $0.00 $99.73K
YoY Change -100.0% -100.0% -18.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.770M $3.420M $369.0K
Total Long-Term Liabilities $0.00 $0.00 $99.73K
Total Liabilities $4.974M $3.420M $4.665M
YoY Change 6.62% -26.77% -36.29%
SHAREHOLDERS EQUITY
Retained Earnings -$121.8M -$115.6M
YoY Change 5.36% 7.88%
Common Stock $292.0K $205.0K
YoY Change 42.48% 9.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $871.2K $21.36M $4.561M
YoY Change
Total Liabilities & Shareholders Equity $5.845M $24.78M $9.226M
YoY Change -36.64% 168.47% -52.8%

Cashflow Statement

Concept 2017 Q2 2017 2016 Q2
OPERATING ACTIVITIES
Net Income -$3.878M -$21.21M -$1.150M
YoY Change 237.22% 115.44% 26.37%
Depreciation, Depletion And Amortization $7.000K $39.00K $10.00K
YoY Change -30.0% 387.5% -75.0%
Cash From Operating Activities -$510.0K -$15.94M -$720.0K
YoY Change -29.17% 80.18% -70.25%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $237.0K $0.00
YoY Change 558.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $60.00K $0.00
YoY Change
Cash From Investing Activities $0.00 -$114.0K $0.00
YoY Change 216.67% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00
YoY Change
Common Stock Issuance & Retirement, Net $17.01M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K 37.95M 0.000
YoY Change 289.79% -100.0%
NET CHANGE
Cash From Operating Activities -510.0K -15.94M -720.0K
Cash From Investing Activities 0.000 -114.0K 0.000
Cash From Financing Activities 300.0K 37.95M 0.000
Net Change In Cash -210.0K 21.90M -720.0K
YoY Change -70.83% 2458.53% -125.09%
FREE CASH FLOW
Cash From Operating Activities -$510.0K -$15.94M -$720.0K
Capital Expenditures $0.00 $237.0K $0.00
Free Cash Flow -$510.0K -$16.17M -$720.0K
YoY Change -29.17% 82.12% -75.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
330301 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
256376 USD
CY2016Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3240000 USD
CY2017Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
9800 USD
CY2016Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
50770 USD
CY2017Q2 us-gaap Assets
Assets
5845200 USD
CY2016Q2 us-gaap Assets
Assets
9225952 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
191597 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
90305 USD
CY2017Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2200000 USD
CY2017 svon Finitelived Intangible Assets Written Off
FinitelivedIntangibleAssetsWrittenOff
0 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
79403 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-223280 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
101292 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
76228 USD
CY2016 svon Deferred Rent
DeferredRent
62778 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1100000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-777610 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3334626 USD
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-533 USD
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2767 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1408936 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1606043 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3170499 USD
CY2015 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
45599 USD
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728 USD
CY2017Q2 us-gaap Liabilities
Liabilities
4973994 USD
CY2016Q2 us-gaap Liabilities
Liabilities
4665294 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
204964 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119983399 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121824326 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115630059 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
4560658 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9225952 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
251223 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171820 USD
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
956575 USD
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 USD
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22310 USD
CY2017 us-gaap Licenses Revenue
LicensesRevenue
0 USD
CY2016 us-gaap Licenses Revenue
LicensesRevenue
75000 USD
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
4592869 USD
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
11269983 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-4592869 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-11194983 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20322714 shares
CY2015 us-gaap Licenses Revenue
LicensesRevenue
75000 USD
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
18151736 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-18076736 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
733661 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2182989 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4568435 USD
CY2017 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2016 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
5780951 USD
CY2015 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
8121966 USD
CY2016 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
254027 USD
CY2016 svon Finitelived Intangible Assets Written Off
FinitelivedIntangibleAssetsWrittenOff
0 USD
CY2015 svon Finitelived Intangible Assets Written Off
FinitelivedIntangibleAssetsWrittenOff
-2290836 USD
CY2017 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
651484 USD
CY2015 us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
12405 USD
CY2017 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2600000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1925110 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
156678 USD
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44075 USD
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
93394 USD
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5780951 USD
CY2017 svon Writeoff Of Prepaid Research Supplies
WriteoffOfPrepaidResearchSupplies
0 USD
CY2016 svon Writeoff Of Prepaid Research Supplies
WriteoffOfPrepaidResearchSupplies
0 USD
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2016 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
0 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-141728 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
177074 USD
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8121966 USD
CY2015 svon Writeoff Of Prepaid Research Supplies
WriteoffOfPrepaidResearchSupplies
669750 USD
CY2015 svon Deferred Rent
DeferredRent
-85088 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
480681 USD
CY2016 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1700000 USD
CY2015 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1040000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-680000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-8267929 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
80108 USD
CY2017 svon Deferred Rent
DeferredRent
22310 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-155496 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3676215 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1152397 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2523818 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-18063785 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-48208 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-669147 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-507121 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7344696 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-259587 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4827569 USD
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1700000 USD
CY2015 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2290836 USD
CY2016 svon Unrealized Gain Loss On Stock Rights
UnrealizedGainLossOnStockRights
254027 USD
CY2015 svon Unrealized Gain Loss On Stock Rights
UnrealizedGainLossOnStockRights
12405 USD
CY2017 svon Unrealized Gain Loss On Warrant Derivatives
UnrealizedGainLossOnWarrantDerivatives
249025 USD
CY2016 svon Unrealized Gain Loss On Warrant Derivatives
UnrealizedGainLossOnWarrantDerivatives
1993560 USD
CY2015 svon Unrealized Gain Loss On Warrant Derivatives
UnrealizedGainLossOnWarrantDerivatives
3313 USD
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-8071 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-75000 USD
CY2017 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-40970 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-680000 USD
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2600000 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1040000 USD
CY2017Q2 svon Development Stage Enterprise Deficit Accumulated During Development Stages
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStages
121824326 USD
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21613659 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13472524 shares
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80108 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
156678 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
480681 USD
CY2017 svon Common Stock Proceeds To Warrants
CommonStockProceedsToWarrants
0 USD
CY2016 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2500 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
47500 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
136946 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122641 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
75000 USD
CY2017 svon Common Stock Proceeds To Stock Rights
CommonStockProceedsToStockRights
0 USD
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2502047 USD
CY2016 svon Common Stock Proceeds To Warrants
CommonStockProceedsToWarrants
559261 USD
CY2016 svon Common Stock Proceeds To Stock Rights
CommonStockProceedsToStockRights
142854 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
281313 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
256805 USD
CY2017 us-gaap Depreciation
Depreciation
44075 USD
CY2014Q4 svon Acquired Research And Development
AcquiredResearchAndDevelopment
9800000 USD
CY2014Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
283393 USD
CY2014Q4 us-gaap Goodwill
Goodwill
13902917 USD
CY2014Q4 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
8121966 USD
CY2015Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2800000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
42598 USD
CY2017 svon Stock Issued During Period Shares Stock Dividend
StockIssuedDuringPeriodSharesStockDividend
212482 shares
CY2017Q2 svon Preferred Stock Stated Value Per Share
PreferredStockStatedValuePerShare
1000
CY2017 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.1 pure
CY2017Q2 svon Stock Conversion Price Per Share
StockConversionPricePerShare
0.75
CY2017Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.01
CY2017 svon Share Reserve Increase
ShareReserveIncrease
0.05 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.25 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
392860 shares
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
47345 USD
CY2015 svon Probability To Achieve Employee Target Goals
ProbabilityToAchieveEmployeeTargetGoals
0.81 pure
CY2014Q4 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
237291 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
85504 shares
CY2014Q4 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
51645 USD
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
70350 shares
CY2017 svon Probability To Achieve Employee Target Goals
ProbabilityToAchieveEmployeeTargetGoals
0.81 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
436363 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
475593 shares
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
13483 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.22
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.24
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0.6
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
38352 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M17D
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y7M2D
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5119433 shares
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13769 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P21M
CY2017Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.5 pure
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2590000 USD
CY2017Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27315000 USD
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1415000 USD
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
734000 USD
CY2017Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29464000 USD
CY2017Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2200000 USD
CY2017Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2200000 USD
CY2017Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29464000 USD
CY2017Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2200000 USD
CY2016Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26096000 USD
CY2016Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1386000 USD
CY2016Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
1281000 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
285356 USD
CY2017 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
149728 USD
CY2016 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2015 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
0 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
27489929 USD
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
12224794 USD
CY2017 us-gaap Dividends Common Stock
DividendsCommonStock
9502 USD
CY2016 us-gaap Dividends Common Stock
DividendsCommonStock
6335 USD
CY2015 us-gaap Dividends Common Stock
DividendsCommonStock
14500 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198 pure
CY2015 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6335 USD
CY2016 us-gaap Dividends Preferred Stock
DividendsPreferredStock
9502 USD
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
10419 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
80108 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
156678 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
480681 USD
CY2016Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28763000 USD
CY2016Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
3240000 USD
CY2016Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3240000 USD
CY2016Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28763000 USD
CY2016Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3240000 USD
CY2017Q2 us-gaap Notes Payable Current
NotesPayableCurrent
407122 USD
CY2016Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2017Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1844974 USD
CY2016Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20496385 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20496385 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29202799 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29202799 shares
CY2017 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
-1175522 USD
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1417922 USD
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4827569 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1152397 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0600 pure
CY2015 svon Allocation Of Common Stock Proceeds To Warrant Liability
AllocationOfCommonStockProceedsToWarrantLiability
1742703 USD
CY2016 svon Allocation Of Common Stock Proceeds To Warrant Liability
AllocationOfCommonStockProceedsToWarrantLiability
559261 USD
CY2015 svon Allocation Of Common Stock Proceeds To Derivative Stock Right
AllocationOfCommonStockProceedsToDerivativeStockRight
775062 USD
CY2016 svon Allocation Of Common Stock Proceeds To Derivative Stock Right
AllocationOfCommonStockProceedsToDerivativeStockRight
142854 USD
CY2015 svon Deemed Dividends On Preferred Stock
DeemedDividendsOnPreferredStock
0 USD
CY2016 svon Deemed Dividends On Preferred Stock
DeemedDividendsOnPreferredStock
0 USD
CY2017 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1417922 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
285356 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1152397 USD
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4827569 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.69 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.46 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.53 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017 svon Maturity Of Cash And Cash Equivalents
MaturityOfCashAndCashEquivalents
P90D
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
743561 USD
CY2016 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0 USD
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332292 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
349359 USD
CY2016 us-gaap Depreciation
Depreciation
93394 USD
CY2015 us-gaap Depreciation
Depreciation
152097 USD
CY2016Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1000000 USD
CY2016Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2981000 USD
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
17900 USD
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6750 USD
CY2015 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
998 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2296470 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1841728 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.49
CY2015 svon Common Stock Proceeds To Warrants
CommonStockProceedsToWarrants
1742703 USD
CY2015 svon Common Stock Proceeds To Stock Rights
CommonStockProceedsToStockRights
775062 USD
CY2017 svon Common Stock Proceeds To Warrants And Conversion
CommonStockProceedsToWarrantsAndConversion
0 USD
CY2016 svon Common Stock Proceeds To Warrants And Conversion
CommonStockProceedsToWarrantsAndConversion
135701 USD
CY2015 svon Common Stock Proceeds To Warrants And Conversion
CommonStockProceedsToWarrantsAndConversion
790507 USD
CY2017 us-gaap Stock Issued1
StockIssued1
0 USD
CY2016 us-gaap Stock Issued1
StockIssued1
0 USD
CY2015 us-gaap Stock Issued1
StockIssued1
0 USD
CY2017 us-gaap Interest Paid
InterestPaid
0 USD
CY2016 us-gaap Interest Paid
InterestPaid
0 USD
CY2015 us-gaap Interest Paid
InterestPaid
137 USD
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y4M24D
CY2015 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
CY2016 us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0073 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0064 pure
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.1520 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.1090 pure
CY2015 svon Share Based Compensation Shares Authorized Under Warrants Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsGrantedExercisePrice
1.50
CY2017 svon Share Based Compensation Shares Authorized Under Warrants Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsGrantedExercisePrice
0
CY2017 svon Share Based Compensation Shares Authorized Under Warrants Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisedInPeriodExercisePrice
0
CY2016 svon Share Based Compensation Shares Authorized Under Warrants Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisedInPeriodExercisePrice
0
CY2015 svon Share Based Compensation Shares Authorized Under Warrants Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisedInPeriodExercisePrice
0
CY2017 svon Share Based Compensation Shares Authorized Under Warrants Cancelled Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsCancelledExercisePrice
0
CY2016 svon Share Based Compensation Shares Authorized Under Warrants Cancelled Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsCancelledExercisePrice
0
CY2015 svon Share Based Compensation Shares Authorized Under Warrants Cancelled Exercise Price
ShareBasedCompensationSharesAuthorizedUnderWarrantsCancelledExercisePrice
0
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.73
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.41
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
289.09
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.45
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.31
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3590 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1626919 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
485682 shares
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016 svon Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
151588 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
43775 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
436363 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017 svon Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
28140 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
6194 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1228739 shares
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
702000 USD
CY2017 svon Convertible Notes Proceeds To Derivative Liability
ConvertibleNotesProceedsToDerivativeLiability
1101413 USD
CY2016 svon Convertible Notes Proceeds To Derivative Liability
ConvertibleNotesProceedsToDerivativeLiability
0 USD
CY2015 svon Convertible Notes Proceeds To Derivative Liability
ConvertibleNotesProceedsToDerivativeLiability
0 USD
CY2017 svon Issuance Of Common Stock For Interest Payments On Convertible Notes
IssuanceOfCommonStockForInterestPaymentsOnConvertibleNotes
42597 USD
CY2016 svon Issuance Of Common Stock For Interest Payments On Convertible Notes
IssuanceOfCommonStockForInterestPaymentsOnConvertibleNotes
40286 USD
CY2015 svon Issuance Of Common Stock For Interest Payments On Convertible Notes
IssuanceOfCommonStockForInterestPaymentsOnConvertibleNotes
56583 USD
CY2016 svon Stock Issued During Period Shares Stock Dividend
StockIssuedDuringPeriodSharesStockDividend
108576 shares
CY2015 svon Stock Issued During Period Shares Stock Dividend
StockIssuedDuringPeriodSharesStockDividend
59500 shares
CY2016 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
40286 USD
CY2015 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
56583 USD
CY2017 us-gaap Accretion Expense
AccretionExpense
241730 USD
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1100000 USD
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
979304 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1203676 shares
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015 svon Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
552471 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.99
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
11.02
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.22
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.83
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
60.65
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.53
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.38
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.61
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
268377 USD
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2017 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
10419 USD
CY2016 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
9502 USD
CY2015 us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
6335 USD
CY2017 svon Share Based Compensation Shares Authorized Under Stock Option Plans Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantedExercisePrice
0.22
CY2017 svon Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice
0.83
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
1101413 USD
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
0 USD
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.40
CY2017 us-gaap Other Commitments Description
OtherCommitmentsDescription
The agreement included a penalty of 1% per month of the investor’s investment, payable in cash, for every 30 day period up to a maximum of 6% for failure to comply with the terms of the agreement.In the event the listing is not continuously maintained for five years after the closing date, on each monthly anniversary of each such listing default date until the applicable listing default is cured, the Company would pay to each subscriber an amount in cash, as partial liquidated damages equal to 1% of the subscriber’s amounts invested held as of each such date.
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1917238 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.29
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.59
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2319267 shares
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Management Estimates and Judgments</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock-based compensation expense, warrant, derivatives and stock rights liabilities, the determination of the fair value of equity transactions and stock-based awards, the accounting for research and development costs, the accounting for impairment and accrued expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentrations of Credit Risk</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains cash balances at financial institutions, which at times, exceed federally insured limits. At June 30, 2017 the Company&#8217;s cash amount did not exceed FDIC insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.&#160;</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.287 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.171 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0.220 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0.153 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.126 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.084 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.004 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.004 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.007 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.030 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.103 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.288 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.245 pure
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.152 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.076 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2017 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
50000 USD
CY2016 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
CY2015 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
268377 USD
CY2017 us-gaap Preferred Stock Dividend Payment Terms
PreferredStockDividendPaymentTerms
If the dividends are paid in shares of Common Stock, such shares will be priced at the lower of 90% of the average volume weighted-average price for the 20 trading days immediately preceding the payment date.
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.76
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.60
CY2016Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8800000 USD
CY2014 svon Finitelived Intangible Assets Written Off
FinitelivedIntangibleAssetsWrittenOff
2290836 USD
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
397904 USD
CY2016 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
179154 USD
CY2015 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
838925 USD
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6194267 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8447083 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18902710 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6836363 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8947929 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18063785 USD
CY2017Q2 us-gaap Debt Instrument Covenant Description
DebtInstrumentCovenantDescription
12,000,000
CY2017 svon Adjustments To Additional Paid In Capital Reclass Warrant From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassWarrantFromLiabilityToEquity
56066 USD
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
75510 shares
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
22797 shares
CY2017 svon Reclassification Of Warrants To Equity
ReclassificationOfWarrantsToEquity
56066 USD
CY2016 svon Reclassification Of Warrants To Equity
ReclassificationOfWarrantsToEquity
0 USD
CY2015 svon Reclassification Of Warrants To Equity
ReclassificationOfWarrantsToEquity
0 USD
CY2017 svon Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
354389 USD
CY2016 svon Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
0 USD
CY2015 svon Preferred Stock Deemed Dividend
PreferredStockDeemedDividend
0 USD
CY2017Q2 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
312260 USD
CY2017 svon Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Reclassification Of Warrants To Equity
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfWarrantsToEquity
-56066 USD
CY2016 svon Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Reclassification Of Warrants To Equity
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisReclassificationOfWarrantsToEquity
0 USD
CY2017Q2 svon Accrued Research And Development Expen
AccruedResearchAndDevelopmentExpen
0 USD
CY2016Q2 svon Accrued Research And Development Expen
AccruedResearchAndDevelopmentExpen
66409 USD
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200000 USD
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0 USD
CY2017Q2 us-gaap Interest Payable Current
InterestPayableCurrent
20178 USD
CY2016Q2 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2017Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
66200 USD
CY2016Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
74240 USD
CY2017Q2 svon Accrued Dividends Current
AccruedDividendsCurrent
10418 USD
CY2016Q2 svon Accrued Dividends Current
AccruedDividendsCurrent
9502 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33505 USD
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
106225 USD

Files In Submission

Name View Source Status
0001144204-17-052475-index-headers.html Edgar Link pending
0001144204-17-052475-index.html Edgar Link pending
0001144204-17-052475.txt Edgar Link pending
0001144204-17-052475-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svon-20170630.xml Edgar Link completed
svon-20170630.xsd Edgar Link pending
svon-20170630_cal.xml Edgar Link unprocessable
svon-20170630_def.xml Edgar Link unprocessable
svon-20170630_lab.xml Edgar Link unprocessable
svon-20170630_pre.xml Edgar Link unprocessable
v475709_10k.htm Edgar Link pending
v475709_ex2-3.htm Edgar Link pending
v475709_ex23-1.htm Edgar Link pending
v475709_ex31-1.htm Edgar Link pending
v475709_ex31-2.htm Edgar Link pending
v475709_ex32-1.htm Edgar Link pending
v475709_ex32-2.htm Edgar Link pending